{"product_id":"600062ss-business-model-canvas","title":"China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS): Canvas Business Model","description":"\u003cp\u003eChina Resources Double-Crane Pharmaceutical Co., Ltd. stands as a key player in the pharmaceutical industry, leveraging a well-rounded Business Model Canvas that highlights its intricate web of partnerships, innovative activities, and robust value propositions. With a commitment to quality and a diverse product range, this company not only meets the needs of healthcare providers and patients but also navigates the complexities of regulatory landscapes and market demands. Discover how each component of their business model intertwines to drive success in a competitive environment below.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eIn the pharmaceutical industry, key partnerships are essential for enhancing operational efficiency and maintaining competitiveness. China Resources Double-Crane Pharmaceutical Co.,Ltd. has established a network of strategic collaborations that support its business objectives.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\n\u003cp\u003eChina Resources Double-Crane Pharmaceutical relies on various raw material suppliers for the production of its pharmaceutical products. In 2022, the company sourced over \u003cstrong\u003e80%\u003c\/strong\u003e of its active pharmaceutical ingredients (APIs) from domestic suppliers, while approximately \u003cstrong\u003e20%\u003c\/strong\u003e came from international markets. This diversification helps mitigate risks associated with supply chain disruptions.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\n\u003cp\u003eThe company collaborates with leading research institutions to foster innovation in drug development. In 2021, China Resources Double-Crane invested approximately \u003cstrong\u003e¥200 million\u003c\/strong\u003e (around \u003cstrong\u003e$31 million\u003c\/strong\u003e) in joint research projects aimed at developing new therapies. These partnerships have enabled the company to access cutting-edge research and expedite the development of novel drugs.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\n\u003cp\u003eEngagement with government health departments is crucial for regulatory compliance and market access. China Resources Double-Crane has established partnerships with various health authorities across China, allowing the company to navigate the regulatory landscape effectively. As of 2023, over \u003cstrong\u003e95%\u003c\/strong\u003e of its products are registered with the National Medical Products Administration (NMPA), facilitating smoother market entry and distribution.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Companies\u003c\/h3\u003e\n\n\u003cp\u003eTo ensure effective distribution of its pharmaceutical products, China Resources Double-Crane partners with numerous distribution companies. The company operates with a network of over \u003cstrong\u003e300 distributors\u003c\/strong\u003e across China, which play a vital role in reaching both urban and rural markets. In 2022, the distribution segment accounted for approximately \u003cstrong\u003e40%\u003c\/strong\u003e of the company's total revenue, which was reported at \u003cstrong\u003e¥17 billion\u003c\/strong\u003e (about \u003cstrong\u003e$2.63 billion\u003c\/strong\u003e).\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003ePartnership Type\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancial Impact\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Material Suppliers\u003c\/td\u003e\n        \u003ctd\u003e80% domestic, 20% international\u003c\/td\u003e\n        \u003ctd\u003eCost efficiency through bulk purchasing\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Institutions\u003c\/td\u003e\n        \u003ctd\u003eInvestment of ¥200 million in 2021\u003c\/td\u003e\n        \u003ctd\u003eAccelerated drug development\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eGovernment Health Departments\u003c\/td\u003e\n        \u003ctd\u003e95% product registration with NMPA\u003c\/td\u003e\n        \u003ctd\u003eImproved market access\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Companies\u003c\/td\u003e\n        \u003ctd\u003e300+ distributors in China\u003c\/td\u003e\n        \u003ctd\u003e40% of total revenue (~¥17 billion in 2022)\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese strategic key partnerships enable China Resources Double-Crane Pharmaceutical Co.,Ltd. to streamline its operations, enhance its product offerings, and maintain a competitive edge in the pharmaceutical landscape.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eChina Resources Double-Crane Pharmaceutical Co., Ltd. engages in several key activities to deliver value in the pharmaceutical industry.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\u003cp\u003eThe company invests significantly in research and development (R\u0026amp;D), which forms the backbone of its innovation strategy. In 2022, the R\u0026amp;D expenditure was reported at approximately \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e, reflecting an increase of about \u003cstrong\u003e15%\u003c\/strong\u003e compared to the previous year. The focus areas of R\u0026amp;D include both traditional Chinese medicine and modern pharmaceutical products.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing of Drugs\u003c\/h3\u003e\n\u003cp\u003eManufacturing is a core activity for China Resources Double-Crane. The company operates multiple manufacturing facilities across China, with a production capacity of over \u003cstrong\u003e1 billion units\u003c\/strong\u003e annually. In 2022, the revenue generated from drug manufacturing reached approximately \u003cstrong\u003eRMB 3.2 billion\u003c\/strong\u003e, contributing significantly to the overall revenue. The company produces a wide range of pharmaceutical products including over-the-counter drugs, prescription medications, and herbal products.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eYear\u003c\/th\u003e\n    \u003cth\u003eProduction Capacity (Units)\u003c\/th\u003e\n    \u003cth\u003eRevenue from Manufacturing (RMB billion)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2020\u003c\/td\u003e\n    \u003ctd\u003e900 million\u003c\/td\u003e\n    \u003ctd\u003e2.8\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2021\u003c\/td\u003e\n    \u003ctd\u003e950 million\u003c\/td\u003e\n    \u003ctd\u003e3.0\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e2022\u003c\/td\u003e\n    \u003ctd\u003e1 billion\u003c\/td\u003e\n    \u003ctd\u003e3.2\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eQuality Assurance\u003c\/h3\u003e\n\u003cp\u003eQuality assurance is critical in the pharmaceutical sector. China Resources Double-Crane has established stringent quality control measures compliant with both domestic and international standards. The company has achieved certification under the Good Manufacturing Practice (GMP) guidelines, ensuring that all products meet established safety and efficacy standards. As of 2022, the company reported a \u003cstrong\u003e99.5%\u003c\/strong\u003e compliance rate during audits for quality assurance processes.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003cp\u003eRegulatory compliance is a vital function that ensures all products are approved for market release. The company dedicates a comprehensive team to navigate regulatory requirements set forth by the National Medical Products Administration (NMPA) in China. As of 2023, China Resources Double-Crane has successfully registered over \u003cstrong\u003e200\u003c\/strong\u003e products with the NMPA, navigating the complex regulatory landscape effectively, which is critical for sustaining production and market entry.\u003c\/p\u003e \n\n\u003cp\u003eIn summary, China Resources Double-Crane Pharmaceutical Co., Ltd. demonstrates a robust framework of key activities that drive its business operations, focusing on R\u0026amp;D, manufacturing, quality assurance, and regulatory compliance to maintain its competitive edge in the pharmaceutical market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eSkilled workforce\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. employs over \u003cstrong\u003e10,000\u003c\/strong\u003e personnel across various levels of expertise. Approximately \u003cstrong\u003e30%\u003c\/strong\u003e of the workforce consists of professionals with advanced degrees in pharmaceutical sciences, biochemistry, and related fields. This skilled workforce is crucial for the company’s R\u0026amp;D and production processes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eResearch facilities\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company operates \u003cstrong\u003ethree major research facilities\u003c\/strong\u003e located in Beijing, Shanghai, and Guangdong. These facilities are equipped with state-of-the-art technology, including high-performance liquid chromatography (HPLC) systems and mass spectrometry equipment. In 2022, China Resources Double-Crane invested approximately \u003cstrong\u003e¥500 million\u003c\/strong\u003e (around \u003cstrong\u003e$75 million\u003c\/strong\u003e) in upgrading these research facilities to enhance drug development capabilities.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing plants\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eChina Resources Double-Crane has \u003cstrong\u003efour manufacturing plants\u003c\/strong\u003e strategically located across China, including facilities in Jiangsu and Hunan provinces. The combined production capacity of these plants is over \u003cstrong\u003e1 billion units\u003c\/strong\u003e of pharmaceutical products annually. The plants adhere to the Good Manufacturing Practices (GMP) standards and have passed rigorous audits by international regulatory bodies.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eManufacturing Plant\u003c\/th\u003e\n\u003cth\u003eLocation\u003c\/th\u003e\n\u003cth\u003eProduction Capacity (Units\/Year)\u003c\/th\u003e\n\u003cth\u003eCertification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant 1\u003c\/td\u003e\n\u003ctd\u003eJiangsu\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e400 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGMP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant 2\u003c\/td\u003e\n\u003ctd\u003eHunan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e300 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGMP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant 3\u003c\/td\u003e\n\u003ctd\u003eGuangdong\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGMP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant 4\u003c\/td\u003e\n\u003ctd\u003eBeijing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGMP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntellectual property\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company holds over \u003cstrong\u003e200 patents\u003c\/strong\u003e related to innovative drug formulations and delivery systems as of 2023. These patents have contributed to a competitive advantage in the market, allowing the company to generate revenues exceeding \u003cstrong\u003e¥3 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$450 million\u003c\/strong\u003e) in 2022 from its proprietary products alone. The intellectual property portfolio is crucial to maintaining market share and driving future growth by enabling the launch of new, patented formulations.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eEffective pharmaceutical solutions\u003c\/strong\u003e are a cornerstone of China Resources Double-Crane Pharmaceutical Co., Ltd.’s value proposition. The company focuses on developing innovative drugs that meet patient needs effectively. In 2022, the company reported a revenue of approximately \u003cstrong\u003eRMB 10.85 billion\u003c\/strong\u003e, reflecting a year-on-year growth of \u003cstrong\u003e12%\u003c\/strong\u003e in its prescription drug segment. This growth underscores its strong position in providing effective therapeutic options across various medical fields.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-quality drug manufacturing\u003c\/strong\u003e is another critical aspect. China Resources Double-Crane operates several state-of-the-art manufacturing facilities that comply with international standards. In 2023, the company was awarded the \u003cstrong\u003e'China Quality Award'\u003c\/strong\u003e, highlighting its commitment to quality in pharmaceutical production. Their facilities, which include over \u003cstrong\u003e20 production lines\u003c\/strong\u003e, have a capacity to produce over \u003cstrong\u003e4 billion tablets\u003c\/strong\u003e and \u003cstrong\u003e2 billion capsules\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003cp\u003eWhen it comes to \u003cstrong\u003ecost-effective medication\u003c\/strong\u003e, China Resources Double-Crane actively invests in research and development (R\u0026amp;D) to produce generic drugs that are affordable for patients. The company offers over \u003cstrong\u003e200 generic medications\u003c\/strong\u003e that often cost up to \u003cstrong\u003e30% less\u003c\/strong\u003e than branded alternatives. In 2021, generic drugs accounted for about \u003cstrong\u003e45%\u003c\/strong\u003e of their total sales, demonstrating a robust demand for cost-effective solutions in the pharmaceutical market.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eextensive product range\u003c\/strong\u003e of China Resources Double-Crane is another significant value proposition. The company offers a portfolio that spans therapeutic areas including oncology, cardiovascular diseases, and anti-infective treatments. As of late 2022, they had launched \u003cstrong\u003e15 new products\u003c\/strong\u003e within the year, increasing their product offerings to over \u003cstrong\u003e300 medications\u003c\/strong\u003e across various dosage forms. This diverse portfolio enables the company to cater to a wide array of customer needs and preferences.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eValue Proposition\u003c\/th\u003e\n    \u003cth\u003eDescription\u003c\/th\u003e\n    \u003cth\u003eKey Figures\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEffective Pharmaceutical Solutions\u003c\/td\u003e\n    \u003ctd\u003eInnovative drugs addressing specific medical needs.\u003c\/td\u003e\n    \u003ctd\u003eRevenue: \u003cstrong\u003eRMB 10.85 billion\u003c\/strong\u003e (2022)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHigh-Quality Drug Manufacturing\u003c\/td\u003e\n    \u003ctd\u003eState-of-the-art facilities meeting international standards.\u003c\/td\u003e\n    \u003ctd\u003e20+ production lines; \u003cstrong\u003e4 billion tablets\u003c\/strong\u003e annually\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCost-Effective Medication\u003c\/td\u003e\n    \u003ctd\u003eGeneric drugs providing affordable treatment options.\u003c\/td\u003e\n    \u003ctd\u003e200+ generic medications; \u003cstrong\u003e30% less\u003c\/strong\u003e cost than branded drugs\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eExtensive Product Range\u003c\/td\u003e\n    \u003ctd\u003eDiverse portfolio across various therapeutic areas.\u003c\/td\u003e\n    \u003ctd\u003e300+ medications; \u003cstrong\u003e15 new products\u003c\/strong\u003e launched in 2022\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eChina Resources Double-Crane Pharmaceutical Co., Ltd. actively engages with doctors and healthcare providers to foster strong relationships. The company utilizes a multi-channel approach to connect with these professionals, ensuring they receive timely and relevant updates about products and services. In 2022, the company reported that it maintained relationships with over \u003cstrong\u003e10,000 healthcare professionals\u003c\/strong\u003e across various regions, emphasizing its commitment to engaging with key stakeholders in the healthcare ecosystem.\u003c\/p\u003e\n\n\u003cp\u003eThe company also focuses on direct consumer feedback as part of its customer relationship strategy. Through structured feedback mechanisms, China Resources Double-Crane collects insights from consumers about their experiences and preferences. In its latest report, it noted that approximately \u003cstrong\u003e75%\u003c\/strong\u003e of its consumer base participated in feedback surveys, helping the company tailor its products more effectively to meet customer needs.\u003c\/p\u003e\n\n\u003cp\u003eOnline health forums are another vital component of the customer relationship strategy. China Resources Double-Crane has established a strong online presence through forums and social media platforms. These channels enable them to facilitate discussions on health issues, product inquiries, and new drug information. In the past year, the company reported an engagement rate of \u003cstrong\u003e65%\u003c\/strong\u003e among users, indicating a vibrant interactive community.\u003c\/p\u003e\n\n\u003cp\u003eCustomer service support plays a critical role as well. The company has invested in enhancing its customer service operations, providing both automated and personal assistance. In 2023, China Resources Double-Crane improved its customer service response time, achieving an average of \u003cstrong\u003e2.5 hours\u003c\/strong\u003e for resolving inquiries. This effort was reflected in customer satisfaction ratings, which reached \u003cstrong\u003e88%\u003c\/strong\u003e based on internal surveys.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCustomer Relationship Strategy\u003c\/th\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDoctor and Healthcare Provider Engagement\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10,000+\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eMaintained relationships with over 10,000 healthcare professionals.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Consumer Feedback\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e75% of the consumer base participated in feedback surveys.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Health Forums\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e65%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eEngagement rate of 65% among users in online platforms.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCustomer Service Support\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2.5 hours\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eAverage response time for resolving inquiries.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCustomer Satisfaction Ratings\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e88%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eCustomer satisfaction ratings based on internal surveys.\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eThe channels through which China Resources Double-Crane Pharmaceutical Co., Ltd. operates are vital for delivering its value proposition to customers. The company employs a diversified strategy that encompasses various distribution methods.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Facilities\u003c\/h3\u003e\n\u003cp\u003eChina Resources Double-Crane predominantly supplies its products to over \u003cstrong\u003e12,000 healthcare facilities\u003c\/strong\u003e across China. This includes hospitals, clinics, and specialized treatment centers. In 2022, the total revenue generated from hospital sales was approximately \u003cstrong\u003eRMB 3 billion\u003c\/strong\u003e, contributing to over \u003cstrong\u003e30%\u003c\/strong\u003e of the company's total revenue.\u003c\/p\u003e\n\n\u003ch3\u003ePharmacies\u003c\/h3\u003e\n\u003cp\u003ePharmacy distribution is another crucial channel. As of 2023, the company has established partnerships with more than \u003cstrong\u003e20,000 pharmacies\u003c\/strong\u003e, which includes both chain stores and independent outlets. The sales through pharmacies constituted around \u003cstrong\u003e25% of total sales\u003c\/strong\u003e, amounting to approximately \u003cstrong\u003eRMB 2.5 billion\u003c\/strong\u003e in 2022.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Platforms\u003c\/h3\u003e\n\u003cp\u003eThe rise of e-commerce has significantly influenced China Resources Double-Crane’s strategy. As of 2023, online sales have surged, accounting for approximately \u003cstrong\u003e15%\u003c\/strong\u003e of total revenue, translating to about \u003cstrong\u003eRMB 1.5 billion\u003c\/strong\u003e. The company has leveraged platforms like \u003cstrong\u003eJD.com\u003c\/strong\u003e and \u003cstrong\u003eAlibaba\u003c\/strong\u003e to enhance its online presence, leading to a year-on-year growth rate of \u003cstrong\u003e20%\u003c\/strong\u003e in e-commerce sales in 2022.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003cp\u003eChina Resources Double-Crane utilizes a dedicated sales force that comprises approximately \u003cstrong\u003e1,000 sales representatives\u003c\/strong\u003e. This team engages directly with healthcare providers and pharmacies, facilitating personal relationships and tailored service. The contribution of direct sales to the overall revenue is estimated at around \u003cstrong\u003eRMB 1.8 billion\u003c\/strong\u003e, which is about \u003cstrong\u003e18%\u003c\/strong\u003e of the total sales in 2022.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel\u003c\/th\u003e\n        \u003cth\u003eNumber of Outlets\u003c\/th\u003e\n        \u003cth\u003eRevenue Contribution (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Facilities\u003c\/td\u003e\n        \u003ctd\u003e12,000\u003c\/td\u003e\n        \u003ctd\u003e3 Billion\u003c\/td\u003e\n        \u003ctd\u003e30%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacies\u003c\/td\u003e\n        \u003ctd\u003e20,000\u003c\/td\u003e\n        \u003ctd\u003e2.5 Billion\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Platforms\u003c\/td\u003e\n        \u003ctd\u003eVariable\u003c\/td\u003e\n        \u003ctd\u003e1.5 Billion\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales Force\u003c\/td\u003e\n        \u003ctd\u003e1,000\u003c\/td\u003e\n        \u003ctd\u003e1.8 Billion\u003c\/td\u003e\n        \u003ctd\u003e18%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis multi-faceted channel strategy enables China Resources Double-Crane to optimize its market access and enhance customer relationships effectively.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eThe customer segments for China Resources Double-Crane Pharmaceutical Co., Ltd. are diverse and strategically targeted to maximize market reach and meet varying healthcare needs.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Healthcare Providers\u003c\/h3\u003e\n\u003cp\u003eThis segment represents a significant portion of the customer base for China Resources Double-Crane Pharmaceutical. In 2022, hospitals in China accounted for approximately \u003cstrong\u003e40%\u003c\/strong\u003e of total pharmaceutical sales, translating to a market worth around \u003cstrong\u003e¥1.4 trillion\u003c\/strong\u003e (approximately \u003cstrong\u003e$213 billion\u003c\/strong\u003e). The company supplies a range of products, including prescription medications and biotechnology solutions designed for hospital use.\u003c\/p\u003e\n\n\u003ch3\u003eIndividual Patients\u003c\/h3\u003e\n\u003cp\u003eIndividual patients are increasingly important, especially in the context of chronic disease management. The retail pharmacy market in China has been growing, with a compound annual growth rate (CAGR) of \u003cstrong\u003e6.5%\u003c\/strong\u003e from 2018 to 2023. By 2023, it is projected to reach \u003cstrong\u003e¥550 billion\u003c\/strong\u003e (around \u003cstrong\u003e$83.5 billion\u003c\/strong\u003e). This segment allows for direct engagement with consumers, enhancing brand loyalty and awareness.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Wholesalers\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical wholesalers act as a critical distribution channel for China Resources Double-Crane. They facilitate the reach to pharmacies and other healthcare outlets. In 2021, the wholesale market for pharmaceuticals in China was valued at approximately \u003cstrong\u003e¥1.1 trillion\u003c\/strong\u003e (about \u003cstrong\u003e$167 billion\u003c\/strong\u003e). The company maintains contracts with several major wholesalers, ensuring broad distribution of its products across the country.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Health Programs\u003c\/h3\u003e\n\u003cp\u003eGovernment health programs are a vital segment, especially as China continues to expand its healthcare initiatives. In 2022, the National Health Commission reported that public healthcare expenditure reached around \u003cstrong\u003e¥8.5 trillion\u003c\/strong\u003e (approximately \u003cstrong\u003e$1.3 trillion\u003c\/strong\u003e), with a significant portion allocated to essential medicines and treatment programs. China Resources Double-Crane collaborates with various state-run health programs to supply affordable medications, further expanding its market reach.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eCustomer Segment\u003c\/th\u003e\n    \u003cth\u003eMarket Size\u003c\/th\u003e\n    \u003cth\u003eGrowth Rate\u003c\/th\u003e\n    \u003cth\u003eKey Characteristics\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHospitals and Healthcare Providers\u003c\/td\u003e\n    \u003ctd\u003e¥1.4 trillion ($213 billion)\u003c\/td\u003e\n    \u003ctd\u003e4.5%\u003c\/td\u003e\n    \u003ctd\u003eHigh demand for prescription medications\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eIndividual Patients\u003c\/td\u003e\n    \u003ctd\u003e¥550 billion ($83.5 billion)\u003c\/td\u003e\n    \u003ctd\u003e6.5%\u003c\/td\u003e\n    \u003ctd\u003eGrowing focus on chronic diseases\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Wholesalers\u003c\/td\u003e\n    \u003ctd\u003e¥1.1 trillion ($167 billion)\u003c\/td\u003e\n    \u003ctd\u003e5.2%\u003c\/td\u003e\n    \u003ctd\u003eEssential for distribution networks\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGovernment Health Programs\u003c\/td\u003e\n    \u003ctd\u003e¥8.5 trillion ($1.3 trillion)\u003c\/td\u003e\n    \u003ctd\u003e5.7%\u003c\/td\u003e\n    \u003ctd\u003eFocus on affordable healthcare\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003ch3\u003eManufacturing expenses\u003c\/h3\u003e\n\u003cp\u003eChina Resources Double-Crane Pharmaceutical Co., Ltd. incurs significant manufacturing expenses associated with the production of pharmaceutical products. For the fiscal year ending December 2022, the company's consolidated manufacturing costs amounted to approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e. This includes expenses on raw materials, labor costs, and utilities. The variable costs in manufacturing account for about \u003cstrong\u003e70%\u003c\/strong\u003e of these expenses, while fixed costs contribute around \u003cstrong\u003e30%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and development costs\u003c\/h3\u003e\n\u003cp\u003eInvestment in research and development (R\u0026amp;D) is critical for pharmaceutical companies. In 2022, China Resources Double-Crane allocated roughly \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e towards R\u0026amp;D, representing about \u003cstrong\u003e10%\u003c\/strong\u003e of total revenue. This investment supports the development of new drugs and improving existing products. The company has focused heavily on chronic disease management medications, which has become increasingly competitive in the market.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and distribution expenses\u003c\/h3\u003e\n\u003cp\u003eMarketing and distribution are essential components of the cost structure. In 2022, the company spent approximately \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e on marketing efforts, which is about \u003cstrong\u003e15%\u003c\/strong\u003e of overall costs. Distribution expenses, which involve logistics and transportation, accounted for an additional \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e. This dual focus on marketing and distribution ensures that the products are effectively promoted and readily available to consumers.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory compliance costs\u003c\/h3\u003e\n\u003cp\u003eRegulatory compliance is a crucial aspect of operating within the pharmaceutical industry. China Resources Double-Crane Pharmaceutical Co., Ltd. incurred regulatory compliance costs of around \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e in 2022. This is essential for adhering to guidelines set by the National Medical Products Administration (NMPA) in China and other international regulations.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Category\u003c\/th\u003e\n        \u003cth\u003eAmount (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Expenses\u003c\/td\u003e\n        \u003ctd\u003e1,200,000,000\u003c\/td\u003e\n        \u003ctd\u003e60%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch and Development\u003c\/td\u003e\n        \u003ctd\u003e200,000,000\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing Expenses\u003c\/td\u003e\n        \u003ctd\u003e300,000,000\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDistribution Expenses\u003c\/td\u003e\n        \u003ctd\u003e200,000,000\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n        \u003ctd\u003e100,000,000\u003c\/td\u003e\n        \u003ctd\u003e5%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eChina Resources Double-Crane Pharmaceutical Co.,Ltd. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eChina Resources Double-Crane Pharmaceutical Co., Ltd. has various revenue streams that contribute to its overall financial performance. The company generates income through drug sales, licensing agreements, government contracts, and export sales.\u003c\/p\u003e\n\n\u003ch3\u003eDrug Sales\u003c\/h3\u003e\n\u003cp\u003eAs one of the primary sources of revenue, drug sales significantly impact the company's financial health. In the fiscal year ending December 31, 2022, drug sales accounted for approximately \u003cstrong\u003e80%\u003c\/strong\u003e of the total revenue, generating around \u003cstrong\u003eRMB 11.5 billion\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 1.75 billion\u003c\/strong\u003e). The product portfolio includes prescription medications, over-the-counter drugs, and traditional Chinese medicine.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Agreements\u003c\/h3\u003e\n\u003cp\u003eLicensing agreements also represent a substantial revenue stream. In 2022, the company reported revenue from licensing totaling approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e (around \u003cstrong\u003eUSD 180 million\u003c\/strong\u003e). These agreements often involve the use of patented formulations and technologies developed by China Resources Double-Crane, contributing around \u003cstrong\u003e8%\u003c\/strong\u003e of the total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eGovernment Contracts\u003c\/h3\u003e\n\u003cp\u003eGovernment contracts are an essential revenue source, particularly in the healthcare sector. In 2022, the company secured contracts worth approximately \u003cstrong\u003eRMB 850 million\u003c\/strong\u003e (about \u003cstrong\u003eUSD 130 million\u003c\/strong\u003e), reflecting both the trust placed in the company by governmental health authorities and the need for pharmaceutical supplies during public health initiatives. Government contracts accounted for around \u003cstrong\u003e6%\u003c\/strong\u003e of total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eExport Sales\u003c\/h3\u003e\n\u003cp\u003eExport sales contribute to the company's revenue, with a significant international presence. In the last fiscal year, export sales reached approximately \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e (approximately \u003cstrong\u003eUSD 90 million\u003c\/strong\u003e), representing around \u003cstrong\u003e4%\u003c\/strong\u003e of the total revenue. The company exports to various markets, including Southeast Asia, Europe, and North America, which helps diversify its income streams.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRevenue Source\u003c\/th\u003e\n    \u003cth\u003eFY 2022 Revenue (RMB)\u003c\/th\u003e\n    \u003cth\u003eFY 2022 Revenue (USD)\u003c\/th\u003e\n    \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDrug Sales\u003c\/td\u003e\n    \u003ctd\u003e11.5 billion\u003c\/td\u003e\n    \u003ctd\u003e1.75 billion\u003c\/td\u003e\n    \u003ctd\u003e80%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLicensing Agreements\u003c\/td\u003e\n    \u003ctd\u003e1.2 billion\u003c\/td\u003e\n    \u003ctd\u003e180 million\u003c\/td\u003e\n    \u003ctd\u003e8%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGovernment Contracts\u003c\/td\u003e\n    \u003ctd\u003e850 million\u003c\/td\u003e\n    \u003ctd\u003e130 million\u003c\/td\u003e\n    \u003ctd\u003e6%\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eExport Sales\u003c\/td\u003e\n    \u003ctd\u003e600 million\u003c\/td\u003e\n    \u003ctd\u003e90 million\u003c\/td\u003e\n    \u003ctd\u003e4%\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45690799030421,"sku":"600062ss-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/600062ss-business-model-canvas.png?v=1739134118","url":"https:\/\/dcf-model.com\/fr\/products\/600062ss-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}